Sorafenib
- PDF / 169,496 Bytes
- 1 Pages / 595.245 x 841.846 pts (A4) Page_size
- 6 Downloads / 145 Views
1 S
Tumour lysis syndrome: case report A 49-year-old man developed tumour lysis syndrome (TLS) during treatment with sorafenib for metastatic hepatocellular carcinoma (HCC). The man was admitted to a hospital via the emergency department, where he presented with various symptoms. Based on investigations, he was diagosed with metastatic HCC. On the day of HCC diagnosis (day 0), he was started on palliative therapy with sorafenib 200mg twice daily [route not stated]. On day 7, he presented to the clinic for follow-up. He underwent various investigations, which showed several metabolic abnormalities, indicating tumour lysis syndrome. The man was admitted to the hospital and treated with rasburicase, furosemide, sodium polystyrene sulfonate and midodrine. However, his condition continued to deteriorate with occurence of oliguria and acidosis. He also developed severe anasarca and associated hypoxia. He refused intubation and dialysis, and left the hospital against medical advice on day 6. On day 14, he was brought back to the emergency room, when he suffered a cardiopulmonary arrest. He underwent investigations on the same day. However, he died of TLS and cardiopulmonary arrest. Imam SZ, et al. Sorafenib-induced tumor lysis syndrome in a patient with metastatic hepatocellular carcinoma. Hematology/Oncology and Stem Cell Therapy 13: 168-170, 803504479 No. 3, Sep 2020. Available from: URL: http://doi.org/10.1016/j.hemonc.2018.03.004
0114-9954/20/1824-0001/$14.95 Adis © 2020 Springer Nature Switzerland AG. All rights reserved
Reactions 3 Oct 2020 No. 1824
Data Loading...
